Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors

Human Immunology

Volumn 74, Issue 1, 2013, Pages 70-74

  Mielczarek Palacz, Aleksandra ^a   Sikora, Justyna ^a   Kondera Anasz, Zdzisława ^a   Hauza, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CD30 LIGAND; CD40 ANTIGEN; CD40 LIGAND;

ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYST FLUID; CYSTADENOMA; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; OVARY TUMOR; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD30; ANTIGENS, CD40; CASE-CONTROL STUDIES; CD30 LIGAND; CD40 LIGAND; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN CYSTS; OVARIAN NEOPLASMS; SOLUBILITY; TERATOMA;

EID: 84870933078     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.10.004     Document Type: Article

References (29)

1. Kwong J., Chan F.L., Wong K.K., Birrer M.J., Archibald K.M., Balkwill F.R., et alInflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cellsNeoplasia 2009, 11:529-541.
2. Fulda SCell death in hematological tumorsApoptosis 2009, 14:409-423.
3. Grewal I.S. Overview of TNF superfamily: a chest full of potential therapeutic targetsAdv Exp Med Biol 2009, 647:1-7.
4. Chatzigeorgiou A., Lyberi M., Chatzilymperis G., Nezos A., Kamper ECD40/CD40L signaling and its implication in health and diseaseBioFactors 2009, 35:474-483.
5. Younes ACD30-targeted antibody therapyCurr Opin Oncol 2011, 23:587-593.
6. Deutsch Y.E., Tadmor T., Podach E.R., Rosenblatt J.DCD30: an important new target in hematologic malignancesLeuk Lymphoma 2011, 52:1641-1654.
7. Oflazoglu E., Grewal J.S., Gerber HTargeting CD30/CD30L in oncology and autoimmune and inflammatory diseasesAdv Exp Med Biol 2009, 647:174-185.
8. Peters A.L., Stunz L.L., Bishop G.ACD40 and autoimmunity: the dark side of a great activatorSemin Immunol 2009, 21:293-300.
9. Suttles J., Stout R.D. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesisSemin Immunol 2009, 21:257-264.
10. Loskog A., Tötterman T.HCD40L - a multipotent molecule for tumor therapyEndocr Metab Immune Disord Drug Targets 2007, 7:23-82.
11. Ferroni P., Santilli F., Guadagni F., Basili S., Davì GContribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesisCurr Med Chem 2007, 14:2170-2180.
12. Rizvi M., Pathak D., Freedman J.E., Chakrabarti SCD40-CD40 ligand interactions in oxidative stress, inflammation and vascular diseaseTrends Mol Med 2008, 14:530-538.
13. Bukovsky AImmune maintenance of self in morphostasis of distinct tissues, tumour growth and regenerative medicineScand J Immunol 2001, 73:159-189.
14. Fan H.Y., Richards J.S. Minireview: physiological and pathological actions of RAS in the ovaryMol Endocrinol 2010, 24:286-298.
15. Ciferská H., Horák P., Hermanová Z., Ordeltová M., Zadrazil J., Tichý T., et alThe levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic valueClin Rheumatol 2007, 26(5):723-728.
16. Mielczarek-Palacz A., Kondera-Anasz Z., Sikora J., Sodowski K., Switała J., Kubina RConcentration of soluble ligand for receptor CD30 (sCD30L)-marker of apoptosis in women with ovarian tumorGinekol Pol 2009, 80(7):494-497.
17. Purdue M.P., Lan Q., Martinez-Maza O., Oken M.M., Hocking W., Huang W.Y., et alA prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphomaBlood 2009 Sep 24, 114(13):2730-2732.
18. Haque T., Chaggar T., Schafers J., Atkinson C., McAulay K.A., Crawford D.H. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseasesJ Med Virol 2011 Feb, 83(2):311-316.
19. Migita K., Abiru S., Maeda Y., Nakamura M., Komori A., Ito M., et alElevated serum BAFF levels in patients with autoimmune hepatitisHum Immunol 2007 Jul, 68(7):586-591.
20. Melichar B., Patenia R., Gallardo S., Melicharová K., Hu W., Freedman R.S. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell linesGynecol Oncol 2007, 104:707-713.
21. Jiang E., He X., Chen X., Sun G., Wu H., Wei Y., et alExpression of CD40 in ovarian cancer and adenovirus-mediated CD40 ligand therapy on ovarian cancer in vitroTumori 2008, 94:356-361.
22. Gallagher N.J., Eliopoulos A.G., Agathangelo A., Oates J., Crocker J., Young L.SCD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretionMol Pathol 2002, 55:110-120.
23. Hakkarainen T., Hemminki A., Pereboev A.V., Barker S.D., Asiedu C.K., Strong T.V., et alCD40 is expressed on ovarian cancer cells and can be utilized for targeting adenovirusesClin Cancer Res 2003, 9:619-624.
24. Ciaravino G., Bhat M., Manbeian C.A., Teng N.N. Differential expression of CD40 and CD95 in ovarian carcinomaEur J Gynaecol Oncol 2004, 25:27-32.
25. Toutirais O., Gervais A., Cabillic F., Le Gallo M., Coudrais A., Levêque J., et alEffects of CD40 binding on ovarian carcinoma cell growth and cytokine production in vitroClin Exp Immunol 2007, 149:372-377.
26. Orvieto R., Schachter B., Yulzari-Roll V., La Marca A., Bar J., Fisch BSoluble CD40 ligand levels during controlled ovarian hyperstimulation - a possible culprit of systemic inflammationAm J Reprod Immunol 2006, 56:243-248.
27. Roselli M., Mineo T.C., Basili S., Martini F., Mariotti S., Aloe S., et alSoluble CD40 ligand plasma levels in lung cancerClin Cancer Res 2004, 10:610-614.
28. Caggiari L., Guidoboni M., Vaccher E., Barzan L., Franchin G., Gloghini A., et alHigh serum levels of CD40-L in patients with undifferentiated nasopharyngeal carcionoma: pathologic and clinical relevanceInfect Agent Cancer 2007, 2:5-16.
29. Hock B.D., McKenzie J.L., Patton N.W., Drayson M., Taylor K., Wakeman C., et alCirculating levels and clinical significance of soluble CD40 in patients with hematologic malignanciesCancer 2006, 106:2148-2157.